Hamidou Yannis, Sobhy Danial Jean Marc, Balcaen Thibault, Liabeuf Sophie, Laville Solène, Jesson Claire, Bruy Pierre Antoine, Farnos Camille, Doussiere Marie, Goeb Vincent
Department of Rheumatology, University Hospital of Amiens, 80054 Amiens, France.
Department of Medical Information, University Hospital of Amiens, 80054 Amiens, France.
J Clin Med. 2025 Mar 15;14(6):2000. doi: 10.3390/jcm14062000.
: Inflammatory pathologies are at the center of various medical specialties and benefit from conventional treatments as well as biological treatments. These latter ones have often been the subject of studies yielding heterogeneous results regarding their infectious and mortality risks. This work aims to describe mortality and its causes in patients afflicted by inflammatory pathologies, receiving either conventional or biological therapy during their first stay in intensive care units. : Our study was conducted using the French national health database, encompassing all hospital stays on a national scale. All comparisons between conventional treatment and biological therapies were performed using the Chi-square test, Fisher's exact test, or Student's -test. : In total, 13,816 patients were included. Within 90 days of the first admission to the intensive care/reanimation service, 11.6% of the patients died, including 9.4% within 30 days and 7.3% during hospitalization. More patients died in the conventional treatment group in comparison to the biological treatment group. More deaths were observed due to cardiovascular (27%), infectious (15%), gastroenterological (12%), and oncological (12%) conditions in the conventional treatment group. However, there were as many deaths from oncological causes (19%) as from cardiovascular causes (19%) in the biological therapy group. Hypertension (66.8%) and renal insufficiency (50.4%) were the most frequently associated comorbidities with mortality. : Mortality in intensive care/reanimation during the initial stay of patients afflicted by inflammatory pathologies is of greater concern for those treated with conventional treatments. Causes of death tend to be more cardiovascular and require more prevention and care management.
炎症性疾病是各种医学专科的核心,受益于传统治疗以及生物治疗。后者常常是研究的主题,但其感染风险和死亡率方面的研究结果往往参差不齐。这项工作旨在描述炎症性疾病患者在首次入住重症监护病房期间接受传统治疗或生物治疗时的死亡率及其原因。
我们的研究使用了法国国家卫生数据库,涵盖全国范围内的所有住院病例。传统治疗与生物治疗之间的所有比较均使用卡方检验、费舍尔精确检验或学生t检验进行。
总共纳入了13816名患者。在首次入住重症监护/复苏服务后的90天内,11.6%的患者死亡,其中30天内死亡的占9.4%,住院期间死亡的占7.3%。与生物治疗组相比,传统治疗组死亡的患者更多。在传统治疗组中,因心血管疾病(27%)、感染(15%)、胃肠疾病(12%)和肿瘤疾病(12%)导致的死亡更多。然而,在生物治疗组中,肿瘤原因导致的死亡(19%)与心血管原因导致的死亡(19%)一样多。高血压(66.8%)和肾功能不全(50.4%)是与死亡率最常相关的合并症。
炎症性疾病患者首次住院期间在重症监护/复苏中的死亡率,对于接受传统治疗的患者来说更令人担忧。死亡原因往往更多是心血管方面的,需要更多的预防和护理管理。